skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Emerging clinical role of ranolazine in the management of angina

Review

(2280) Views  (711) Full article downloads

Authors: David S Vadnais, Nanette K Wenger

Published Date October 2010 Volume 2010:6 Pages 517 - 530
DOI: http://dx.doi.org/10.2147/TCRM.S4468

David S Vadnais, Nanette K Wenger

Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia, USA

Abstract: Chronic stable angina is an exceedingly prevalent condition with tremendous clinical, social, and financial implications. Traditional medical therapy for angina consists of beta-blockers, calcium channel blockers, and nitrates. These agents decrease myocardial oxygen demand and ischemia by reducing heart rate, lowering blood pressure, and/or optimizing ventricular loading characteristics. Unique in its mechanism of action, ranolazine is the first new antianginal agent approved for use in the US for chronic angina in over 25 years. By inhibiting the late inward sodium current (INa), ranolazine prevents pathologic intracellular calcium accumulation that leads to ischemia, myocardial dysfunction, and electrical instability. Ranolazine has been proven in multiple clinical trials to reduce the symptoms of angina safely and effectively and to improve exercise tolerance in patients with symptomatic coronary heart disease. These benefits occur without reduction in heart rate and blood pressure or increased mortality. Although ranolazine prolongs the QTc, experimental data indicate that ranolazine may actually be antiarrhythmic. In a large acute coronary syndrome clinical trial, ranolazine reduced the incidence of supraventricular tachycardia, ventricular tachycardia, new-onset atrial fibrillation, and bradycardic events. Additional benefits of ranolazine under investigation include reductions in glycosylated hemoglobin levels and improved left ventricular function. Ranolazine is a proven antianginal medication in patients with symptomatic coronary heart disease, and should be considered as an initial antianginal agent for those with hypotension or bradycardia.

Keywords: chronic angina, myocardial ischemia, ranolazine, pharmacotherapy, antianginal, sodium current






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
ABO and rhesus blood group distribution in Kurds
Diagnostic accuracy of dual-source CT angiography and coronary risk stratification
Wearing facemasks when performing lumbar punctures: a snapshot of current practice amongst trainee doctors
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Zinc oxide nanoparticles as selective killers of proliferating cells
Sudden cardiac death in young athletes
Extended-release ranolazine: critical evaluation of its use in stable angina
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy